Benzylsulfonyl acetate | 68167-37-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzylsulfonyl acetate
• CAS: 68167-37-3
• 化学式: C₉H₁₀O₄S
• 分子量: 214.242
• InChiKey: LVGDEOXDOBTXBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  硫代乙酸苄酯 在 四氧化钌 作用下， 以 四氯化碳 为溶剂， 生成 Benzylsulfonyl acetate
  参考文献：
  名称：

  Sousa Lobo,M.J.; Chaves das Neves,H.J., Tetrahedron Letters, 1978, p. 2171 - 2174

  摘要：

  DOI：

文献信息

• (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof
  申请人：——

  公开号：US20030149109A1

  公开（公告）日：2003-08-07

  Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.

  使用α,β-不饱和芳基磺酮进行预处理可以保护正常细胞免受两类抗癌化疗药物的细胞毒副作用。在患者进行含细胞周期有丝分裂期抑制剂或拓扑异构酶抑制剂的抗癌化疗之前，给予一种细胞保护性磺酮化合物，可以减少或消除抗癌药物对正常细胞的细胞毒副作用。α,β-不饱和芳基磺酮的细胞保护作用使得临床医生可以安全地增加抗癌化疗药物的剂量。
• Styryl sulfone anticancer agents
  申请人：——

  公开号：US20020022666A1

  公开（公告）日：2002-02-21

  Styryl sulfone compounds of the invention selectively inhibit proliferation of tumor cells, and induce apoptosis of tumor cells, while sparing normal cells. The compounds, which are useful in the treatment of cancer and other proliferative disorders, have (a) the formula II: 1 wherein n is zero or one; R 1 is selected from the group consisting of hydrogen, chlorine, fluorine and bromine; R 2 is selected from the group consisting of hydrogen, chlorine, fluorine, bromine, methyl and methoxy; and R 3 is selected from the group consisting of hydrogen, chlorine and fluorine; provided, R 2 may not be methyl or methoxy when R 1 and R 3 are both hydrogen and n is zero or one; and R 1 , R 2 and R 3 may not all be hydrogen when n is one; (b) the formula III: 2 wherein R 1 is selected from the group consisting of hydrogen, chlorine, fluorine and bromine; or (c) or the formula IV: 3 wherein R 1 is selected from the group consisting of fluorine and bromine, and R 2 is selected from the group consisting of 2-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl and 2-nitrophenyl.

  本发明的苯乙烯基磺酰化合物选择性地抑制肿瘤细胞的增殖，并诱导肿瘤细胞凋亡，同时不损害正常细胞。这些化合物在治疗癌症和其他增殖性疾病中很有用，具有以下特征： (a) 公式II： 1 其中 n 是零或一； R 1 选自氢、氯、氟和溴的组； R 2 选自氢、氯、氟、溴、甲基和甲氧基的组；和 R 3 选自氢、氯和氟的组；前提是， 当 R 1 和 R 3 都是氢且 n 是零或一时，R 2 不能是甲基或甲氧基；且 当 n 是一时，R 1 、R 2 和 R 3 不能都是氢； (b) 公式III： 2 其中 R 1 选自氢、氯、氟和溴的组；或 (c) 公式IV： 3 其中 R 1 选自氟和溴的组，R 2 选自2-氯苯基、4-氯苯基、4-氟苯基和2-硝基苯基的组。
• PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS
  申请人：SIRIGIREDDY REDDY

  公开号：US20100152491A1

  公开（公告）日：2010-06-17

  Processes for preparing (E)-2,4,6-(Trimethoxystyryl)-3-O-Phosphate Disodium-4-Methoxybenzyl Sulfones and uses thereof as antiproliferative agents, including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

  制备(E)-2,4,6-(三甲氧基苯乙烯基)-3-O-磷酸二钠-4-甲氧基苯甲基磺酮的方法及其作为抗增殖剂的用途，包括作为抗癌剂，以及作为放射保护和化学保护剂的用途。
• Substituted styryl benzylsulfones for treating proliferative disorders
  申请人：——

  公开号：US20020115643A1

  公开（公告）日：2002-08-22

  Styryl benzylsulfones of formula I are useful as antiproliferative agents, including, for example, anticancer agents: 1 wherein (a) (i) at least three of R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or (b) (i) at least three of R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

  式I的苯基砜基苯乙烯是有用的抗增殖剂，包括例如抗癌剂：其中 (a) (i) R1、R2、R3、R4和R5中至少三个独立地选自卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组，以及所述的R1、R2、R3、R4和R5的余下部分独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组；和 (ii) R6、R7、R8、R9和R10独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组；或 (b) (i) R6、R7、R8、R9和R10中至少三个独立地选自卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组，以及所述的R6、R7、R8、R9和R10的余下部分独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组；和 (ii) R1、R2、R3、R4和R5独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组；或其药学上可接受的盐。
• COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA
  申请人：Reddy E. Premkumar

  公开号：US20100305059A1

  公开（公告）日：2010-12-02

  Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: wherein R 1 is selected from the group consisting of —NH 2 , —NH—CH 2 —CO 2 H, —NH—CH(CH 3 )—CO 2 H, and —NH—C(CH 3 ) 2 —CO 2 H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.

  提供了用于治疗骨髓增生异常综合征和急性髓系白血病的方法和组合物，其中该组合物包括至少一种符合以下式I的化合物：其中R1选自—NH2、—NH—CH2—CO2H、—NH—CH(CH3)—CO2H和—NH—C(CH3)2—CO2H的群组，或者该化合物的药用可接受盐；以及DNA 甲基转移酶抑制剂，或其药用可接受盐。